Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase NA 1Phase 3 1Phase 2 1Phase 1/2 1

Status

Completed 10Terminated 6Unknown 4Recruiting 4Active not recruiting 2

Sponsor Class

OTHER 3INDUSTRY 3

Study Type

Interventional 6

Sponsor

Cancer Type

Genitourinary 23Breast 17Gastrointestinal 10Endocrine 10CNS 10Lymphoid 8Head & Neck 8NET 7Tumor-Agnostic 6Thoracic 5Other hematologic neoplasm 3Dermatologic 3Sarcoma 2Plasma cell 2Other 1Myeloid 1Gynecologic 1Classical hematology 1

Conditions

Neoplasms 5Neoplasm Metastasis 1

Interventions

Gemcitabine 13pembrolizumab 12Capecitabine 9Irinotecan 8Erlotinib Hydrochloride 8Carboplatin 8Blood Specimen Collection 8Nivolumab 7Docetaxel 7Cisplatin 7Cetuximab 7Paclitaxel 6Everolimus 6130-nm albumin-bound paclitaxel 6vadimezan 5Magnetic Resonance Spectroscopy 5Fluorouracil 5Cyclophosphamide 5trametinib 4Leucovorin 4Lapatinib 4Ipilimumab 4Bevacizumab 4Albumin-Bound Paclitaxel 4temsirolimus 3atezolizumab 3abemaciclib 3Trastuzumab 3Radiotherapy 3Radiation 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Terminated × Everolimus × Tumor-Agnostic × Clear all
NCT03839940 2025-01-29

MIST

Alliance for Clinical Trials in Oncology

Phase 3 Terminated
39 enrolled 18 charts
Tumor-Agnostic

Neoplasms

NCT01190241 2020-11-20

TSAP

Amsterdam UMC, location VUmc

Phase NA Terminated
45 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT01376310 2019-02-19

GSK1120212 Rollover Study

Novartis

Phase 2 Terminated
159 enrolled 9 charts
Tumor-Agnostic

Neoplasms

NCT00954512 2018-08-24

Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)

Merck Sharp & Dohme LLC

Phase 1/2 Terminated
15 enrolled 11 charts
Tumor-Agnostic

Neoplasms

NCT00985374 2016-11-02

A Multiple Ascending Dose Study of the mTOR Inhibitor (RAD001) in Combination With R1507 in Patients With Advanced Solid Tumors

Hoffmann-La Roche

Phase 1 Terminated
11 enrolled
Tumor-Agnostic

Neoplasms

NCT01096199 2014-01-22

A Study of TS-1, Cisplatin (CDDP) and RAD001 (Everolimus)

National University Hospital, Singapore

Phase 1 Terminated
35 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡